These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22569473)

  • 1. Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice.
    Beinborn NA; Du J; Wiederhold NP; Smyth HD; Williams RO
    Eur J Pharm Biopharm; 2012 Aug; 81(3):600-8. PubMed ID: 22569473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing.
    Beinborn NA; Lirola HL; Williams RO
    Int J Pharm; 2012 Jun; 429(1-2):46-57. PubMed ID: 22433472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
    Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.
    Carvalho SR; Watts AB; Peters JI; Liu S; Hengsawas S; Escotet-Espinoza MS; Williams RO
    Eur J Pharm Biopharm; 2014 Sep; 88(1):136-47. PubMed ID: 24859653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution.
    Tolman JA; Nelson NA; Son YJ; Bosselmann S; Wiederhold NP; Peters JI; McConville JT; Williams RO
    Eur J Pharm Biopharm; 2009 May; 72(1):199-205. PubMed ID: 19348016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose tolerability of chronically inhaled voriconazole solution in rodents.
    Tolman JA; Nelson NA; Bosselmann S; Peters JI; Coalson JJ; Wiederhold NP; Williams RO
    Int J Pharm; 2009 Sep; 379(1):25-31. PubMed ID: 19524030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation.
    Moon C; Watts AB; Lu X; Su Y; Williams RO
    Mol Pharm; 2019 May; 16(5):1799-1812. PubMed ID: 30925839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.
    Wang YB; Watts AB; Peters JI; Liu S; Batra A; Williams RO
    AAPS PharmSciTech; 2014 Aug; 15(4):981-93. PubMed ID: 24824172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA; Kuhn DM
    Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers.
    Yang W; Tam J; Miller DA; Zhou J; McConville JT; Johnston KP; Williams RO
    Int J Pharm; 2008 Sep; 361(1-2):177-88. PubMed ID: 18556158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
    Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice.
    Duret C; Wauthoz N; Merlos R; Goole J; Maris C; Roland I; Sebti T; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2012 Aug; 81(3):627-34. PubMed ID: 22538097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos).
    Kline Y; Clemons KV; Woods L; Stevens DA; Tell LA
    Med Mycol; 2011 Jul; 49(5):500-12. PubMed ID: 21171838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
    Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
    Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.
    Krishnan Natesan S; Wu W; Cutright JL; Chandrasekar PH
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):272-7. PubMed ID: 22897872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryogenic liquids, nanoparticles, and microencapsulation.
    Purvis T; Vaughn JM; Rogers TL; Chen X; Overhoff KA; Sinswat P; Hu J; McConville JT; Johnston KP; Williams RO
    Int J Pharm; 2006 Oct; 324(1):43-50. PubMed ID: 16814968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.
    Petraitis V; Petraitiene R; Hope WW; Meletiadis J; Mickiene D; Hughes JE; Cotton MP; Stergiopoulou T; Kasai M; Francesconi A; Schaufele RL; Sein T; Avila NA; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2382-91. PubMed ID: 19307368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.
    Kirkpatrick WR; Najvar LK; Vallor AC; Wiederhold NP; Bocanegra R; Pfeiffer J; Perkins K; Kugler AR; Sweeney TD; Patterson TF
    J Antimicrob Chemother; 2012 Apr; 67(4):970-6. PubMed ID: 22240402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
    Chan HM; Duran SH; Walz PH; Ravis WR
    J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole into PLGA nanoparticles: improving agglomeration and antifungal efficacy.
    Peng HS; Liu XJ; Lv GX; Sun B; Kong QF; Zhai DX; Wang Q; Zhao W; Wang GY; Wang DD; Li HL; Jin LH; Kostulas N
    Int J Pharm; 2008 Mar; 352(1-2):29-35. PubMed ID: 18053659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.